Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features
Abstract
:1. Introduction
2. Material and Methods
2.1. Patients
2.2. RT-PCR Methods
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Aguiar Junior, S.; Oliveira, M.M.; Silva, D.R.M.E.; Mello, C.A.L.; Calsavara, V.F.; Curado, M.P. Survival of patients with colorectal cancer in a cancer center. Arq. Gastroenterol. 2020, 57, 172–177. [Google Scholar] [CrossRef] [PubMed]
- Ladabaum, U.; Dominitz, J.A.; Kahi, C.; Schoen, R.E. Strategies for Colorectal Cancer Screening. Gastroenterology 2020, 158, 418–432. [Google Scholar] [CrossRef] [PubMed]
- Valeri, N.; Croce, C.M.; Fabbri, M. Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genom. Proteom. 2009, 6, 195–204. [Google Scholar]
- Moridikia, A.; Mirzaei, H.; Sahebkar, A.; Salimian, J. MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J. Cell. Physiol. 2018, 233, 901–913. [Google Scholar] [CrossRef]
- Zhang, N.; Hu, X.; Du, Y.; Du, J. The role of miRNAs in colorectal cancer progression and chemoradiotherapy. Biomed. Pharmacother. 2021, 134, 111099. [Google Scholar] [CrossRef]
- Howe, K. Extraction of miRNAs from Formalin-Fixed Paraffin-Embedded (FFPE) Tissues. Methods Mol. Biol. 2017, 1509, 17–24. [Google Scholar]
- Chen, H.; Xu, Z.; Liu, D. Small non-coding RNA and colorectal cancer. J. Cell Mol. Med. 2019, 23, 3050–3057. [Google Scholar] [CrossRef]
- Wang, Y.; Huang, L.; Shan, N.; Ma, H.; Lu, S.; Chen, X.; Long, H. Establishing a three-miRNA signature as a prognostic model for colorectal cancer through bioinformatics analysis. Aging (Albany NY) 2021, 13, 19894–19907. [Google Scholar] [CrossRef]
- Moazzendizaji, S.; Sevbitov, A.; Ezzatifar, F.; Jalili, H.R.; Aalii, M.; Hemmatzadeh, M.; Aslani, S.; Gholizadeh Navashenaq, J.; Safari, R.; Hosseinzadeh, R.; et al. Micrornas: Small Molecules With A Large Impact On Colorectal Cancer. Biotechnol. Appl. Biochem. 2021. [Google Scholar] [CrossRef]
- Guo, H.; Chen, Y.; Hu, X.; Qian, G.; Ge, S.; Zhang, J. The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Mol. Cancer 2013, 12, 77. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Wang, Z.; Chen, M.; Peng, L.; Wang, X.; Ma, Q.; Fengli, M.; Jiang, B. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol. Cancer 2012, 11, 23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamada, N.; Noguchi, S.; Mori, T.; Naoe, T.; Maruo, K.; Akao, Y. Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett. 2013, 335, 332–342. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Guo, H.; Qian, G.; Ge, S.; Ji, H.; Hu, X.; Chen, W. MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol. Cancer 2010, 9, 211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gregersen, L.H.; Jacobsen, A.B.; Frankel, L.B.; Wen, J.; Krogh, A.; Lund, A.H. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS ONE 2010, 5, e8836. [Google Scholar] [CrossRef] [Green Version]
- Pagliuca, A.; Valvo, C.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Forte, S.; De Maria, R.; Ricci-Vitiani, L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2013, 32, 4806–4813. [Google Scholar] [CrossRef]
- Noguchi, S.; Mori, T.; Hoshino, Y.; Maruo, K.; Yamada, N.; Kitade, Y.; Naoe, T.; Akao, Y. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 2011, 307, 211–220. [Google Scholar] [CrossRef]
- Wang, Y.; Hu, C.; Cheng, J.; Chen, B.; Ke, Q.; Lv, Z.; Wu, J.; Zhou, Y. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem. Biophys. Res. Commun. 2014, 446, 1255–1260. [Google Scholar] [CrossRef]
- Wang, L.; Shi, Z.M.; Jiang, C.F.; Liu, X.; Chen, Q.D.; Qian, X.; Li, D.M.; Ge, X.; Wang, X.F.; Liu, L.Z.; et al. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 2014, 5, 5416–5427. [Google Scholar] [CrossRef] [Green Version]
- Borralho, P.M.; Kren, B.T.; Castro, R.E.; da Silva, I.B.; Steer, C.J.; Rodrigues, C.M. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009, 276, 6689–6700. [Google Scholar] [CrossRef]
- Qian, X.; Yu, J.; Yin, Y.; He, J.; Wang, L.; Li, Q.; Zhang, L.Q.; Li, C.Y.; Shi, Z.M.; Xu, Q.; et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013, 12, 1385–1394. [Google Scholar] [CrossRef] [Green Version]
- Yu, X.; Zhang, X.; Dhakal, I.B.; Beggs, M.; Kadlubar, S.; Luo, D. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer 2012, 12, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noguchi, S.; Yasui, Y.; Iwasaki, J.; Kumazaki, M.; Yamada, N.; Naito, S.; Akao, Y. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 2013, 328, 353–361. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Yu, X.; Guo, X.; Tian, Z.; Su, M.; Long, Y.; Huang, C.; Zhou, F.; Liu, M.; Wu, X.; et al. Mir-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol. Med. Rep. 2012, 5, 753–760. [Google Scholar] [PubMed]
- Xu, Q.; Liu, L.Z.; Qian, X.; Chen, Q.; Jiang, Y.; Li, D.; Lai, L.; Jiang, B.H. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2012, 40, 761–774. [Google Scholar] [CrossRef]
- Zou, C.; Xu, Q.; Mao, F.; Li, D.; Bian, C.; Liu, L.Z.; Jiang, Y.; Chen, X.; Qi, Y.; Zhang, X.; et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012, 11, 2137–2145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fan, L.; Wu, Q.; Xing, X.; Wei, Y.; Shao, Z. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim. Biophys. Sin. 2012, 44, 407–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boufraqech, M.; Zhang, L.; Jain, M.; Patel, D.; Ellis, R.; Xiong, Y.; He, M.; Nilubol, N.; Merino, M.J.; Kebebew, E. MiR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr. Relat. Cancer 2014, 21, 517–531. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Almeida, M.I.; Calin, G.A. The miR-143/miR-145 cluster and the tumor microenvironment: Unexpected roles. Genome Med. 2016, 8, 29. [Google Scholar] [CrossRef] [Green Version]
- Wen, D.; Li, S.; Jiang, W.; Zhu, J.; Liu, J.; Zhao, S. miR-539 inhibits human colorectal cancer progression by targeting RUNX2. Biomed Pharmacother 2017, 95, 1314–1320. [Google Scholar] [CrossRef]
- La Rocca, G.; Badin, M.; Shi, B.; Xu, S.Q.; Deangelis, T.; Sepp-Lorenzinoi, L.; Baserga, R. Mechanism of growth inhibition by MicroRNA 145: The role of the IGF-I receptor signaling pathway. J. Cell Physiol. 2009, 220, 485–491. [Google Scholar] [CrossRef]
- Longato, L.; de la Monte, S.; Kuzushita, N.; Horimoto, M.; Rogers, A.B.; Slagle, B.L.; Wands, J.R. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009, 49, 1935–1943. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peng, W.; Hu, J.; Zhu, X.D.; Liu, X.; Wang, C.C.; Li, W.H.; Chen, Z.Y. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol. 2014, 35, 2983–2988. [Google Scholar] [CrossRef] [PubMed]
- Akao, Y.; Nakagawa, Y.; Iio, A.; Naoe, T. Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk. Res. 2009, 33, 1530–1538. [Google Scholar] [CrossRef]
- Ibrahim, A.F.; Weirauch, U.; Thomas, M.; Grunweller, A.; Hartmann, R.K.; Aigner, A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011, 71, 5214–5224. [Google Scholar] [CrossRef] [Green Version]
- Akao, Y.; Nakagawa, Y.; Hirata, I.; Iio, A.; Itoh, T.; Kojima, K.; Nakashima, R.; Kitade, Y.; Naoe, T. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010, 17, 398–408. [Google Scholar] [CrossRef] [PubMed]
- Kitade, Y.; Akao, Y. MicroRNAs and their therapeutic potential for human diseases: MicroRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J. Pharmacol. Sci. 2010, 114, 276–280. [Google Scholar] [CrossRef] [Green Version]
- Noh, J.H.; Chang, Y.G.; Kim, M.G.; Jung, K.H.; Kim, J.K.; Bae, H.J.; Eun, J.W.; Shen, Q.; Kim, S.J.; Kwon, S.H.; et al. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013, 335, 455–462. [Google Scholar] [CrossRef]
- Das, A.V.; Pillai, R.M. Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int. 2015, 15, 92. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Zhang, S.; Wang, Q.; Zhang, X. Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. Oncotarget 2017, 8, 42043–42060. [Google Scholar] [CrossRef] [Green Version]
- Safa, A.; Bahroudi, Z.; Shoorei, H.; Majidpoor, J.; Abak, A.; Taheri, M.; Ghafouri Fard, S. miR-1: A comprehensive review of its role in normal development and diverse disorders. Biomed. Pharmacother. 2020, 132, 110903. [Google Scholar] [CrossRef]
- Zhu, D.; Sun, Y.; Zhang, D.; Dong, M.; Jiang, G.; Zhang, X.; Zhou, J. miR-1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor. Oncol. Rep. 2018, 40, 589–598. [Google Scholar] [CrossRef] [PubMed]
- Tagscherer, K.E.; Fassl, A.; Sinkovic, T.; Richter, J.; Schecher, S.; Macher-Goeppinger, S.; Roth, W. MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen. Cancer Cell Int. 2016, 16, 42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xing, Z.; Wang, X.; Liu, J.; Zhang, M.; Feng, K.; Wang, X. Effect of MiR-210 on the Chemosensitivity of Breast Cancer by Regulating JAK-STAT Signaling Pathway. Biomed. Res. Int. 2021, 2021, 7703159. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Pan, W.; Shen, Y.; Chen, Z.; Zhang, L.; Zhang, Y.; Luo, Q.; Ying, X. IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. Cell Cycle 2018, 17, 1212–1219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Contursi, A.; Arconzo, M.; Cariello, M.; Piglionica, M.; D’Amore, S.; Vacca, M.; Graziano, G.; Gadaleta, R.M.; Valanzano, R.; Mariani-Costantini, R.; et al. let-7e downregulation characterizes early phase colonic adenoma in APCMin/+ mice and human FAP subjects. PLoS ONE 2021, 16, e0249238. [Google Scholar]
- Fadaka, A.O.; Pretorius, A.; Klein, A. Biomarkers for Stratification in Colorectal Cancer: MicroRNAs. Cancer Control 2019, 26, 1073274819862784. [Google Scholar] [CrossRef]
- Yiu, A.J.; Yiu, C.Y. Biomarkers in Colorectal Cancer. Anticancer Res. 2016, 36, 1093–1102. [Google Scholar]
- Sur, D.G.; Colceriu, M.; Sur, G.; Aldea, C.; Silaghi, C.; Samasca, G.; Lupan, I.; Căinap, C.; Burz, C.; Irimie, A. MiRNAs roles in the diagnosis, prognosis and treatment of colorectal cancer. Expert Rev. Proteom. 2019, 16, 851–856. [Google Scholar] [CrossRef]
- Eshghifar, N.; Badrlou, E.; Pouresmaeili, F. The roles of miRNAs’ clinical efficiencies in the colorectal cancer pathobiology: A review article. Hum. Antibodies 2020, 28, 273–285. [Google Scholar] [CrossRef]
- Luo, X.; Burwinkel, B.; Tao, S.; Brenner, H. MicroRNA signatures: Novel biomarker for colorectal cancer? Cancer Epidemiol. Biomarkers Prev. 2011, 20, 1272–1276. [Google Scholar] [CrossRef] [Green Version]
- Budzyński, M.; Grenda, A.; Filip, A.A. Cząsteczki mikroRNA jako istotny składnik mechanizmów regulacji ekspresji genów związanych z nowotworami. J. Oncol. 2014, 64, 48–60. [Google Scholar] [CrossRef] [Green Version]
- Avgeris, M.; Mavridis, K.; Tokas, T.; Stravodimos, K.; Fragoulis, E.G.; Scorilas, A. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis 2015, 36, 528–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dimitrova, N.; Gocheva, V.; Bhutkar, A.; Resnick, R.; Jong, R.M.; Miller, K.M.; Bendor, J.; Jacks, T. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2016, 6, 188–201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kojima, S.; Enokida, H.; Yoshino, H.; Itesako, T.; Chiyomaru, T.; Kinoshita, T.; Fuse, M.; Nishikawa, R.; Goto, Y.; Naya, Y.; et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet. 2014, 59, 78–87. [Google Scholar] [CrossRef] [PubMed]
- Su, J.; Liang, H.; Yao, W.; Wang, N.; Zhang, S.; Yan, X.; Feng, H.; Pang, W.; Wang, Y.; Wang, X.; et al. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS ONE 2014, 9, e114420. [Google Scholar] [CrossRef] [PubMed]
- Michael, M.Z.; O’ Connor, S.M.; van Holst Pellekaan, N.G.; Young, G.P.; James, R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 2003, 1, 882–891. [Google Scholar]
- Ng, E.K.; Tsang, W.P.; Ng, S.S.; Jin, H.C.; Yu, J.; Li, J.J.; Röcken, C.; Ebert, M.P.; Kwok, T.T.; Sung, J.J. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 2009, 101, 699–706. [Google Scholar] [CrossRef] [Green Version]
- Jung, E.; Choi, J.; Kim, J.S.; Han, T.S. MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer. Pharmaceuticals 2021, 14, 136. [Google Scholar] [CrossRef]
- Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [Google Scholar] [CrossRef]
- Sun, Y.; Xing, X.; Liu, Q.; Wang, Z.; Xin, Y.; Zhang, P.; Hu, C.; Liu, Y. Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1α/miR-210/Bcl-2 pathway in colon cancer cells. Int. J. Oncol. 2015, 46, 750–756. [Google Scholar] [CrossRef] [Green Version]
- Samadi, P.; Afshar, S.; Amini, R.; Najafi, R.; Mahdavinezhad, A.; Sedighi-Pashaki, A.; Gholami, M.H.; Saidijam, M. Let-7e enhances the radiosensitivity of colorectal cancer cells by directly targeting insulin-like growth factor 1 receptor. J. Cell Physiol. 2019, 234, 10718–10725. [Google Scholar] [CrossRef] [PubMed]
- Hajibabaie, F.; Abedpoor, N.; Assareh, N.; Tabatabaiefar, M.A.; Shariati, L.; Zarrabi, A. The Importance of SNPs at miRNA Binding Sites as Biomarkers of Gastric and Colorectal Cancers: A Systematic Review. J. Pers. Med. 2022, 12, 456. [Google Scholar] [CrossRef] [PubMed]
- Yamazaki, N.; Koga, Y.; Taniguchi, H.; Kojima, M.; Kanemitsu, Y.; Saito, N.; Matsumura, Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget 2021, 8, 6970–6983. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghanbari, R.; Rezasoltani, S.; Hashemi, J.; Mohamadkhani, A.; Tahmasebifar, A.; Arefian, E.; Mobarra, N.; Asadi, J.; Nazemalhosseini Mojarad, E.; Yazdani, Y.; et al. Expression Analysis of Previously Verified Fecal and Plasma Dow-regulated MicroRNAs (miR-4478, 1295–3p, 142-3p and 26a-5p), in FFPE Tissue Samples of CRC Patients. Arch. Iran. Med. 2017, 20, 92–95. [Google Scholar]
- Bayatiani, M.R.; Ahmadi, A.; Aghabozorgi, R.; Seif, F. Concomitant Up-Regulation of Hsa- Mir-374 and Down-Regulation of Its Targets, GSK-3beta and APC, in Tissue Samples of Colorectal Cancer. Rep. Biochem. Mol. Biol. 2021, 9, 408–416. [Google Scholar]
- Boisen, M.K.; Dehlendorff, C.; Linnemann, D.; Schultz, N.A.; Jensen, B.V.; Høgdall, E.V.; Johansen, J.S. MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. BMC Cancer 2015, 15, 1024. [Google Scholar] [CrossRef] [Green Version]
- Nagy, Z.B.; Wichmann, B.; Kalmár, A.; Galamb, O.; Barták, B.K.; Spisák, S.; Tulassay, Z.; Molnár, B. Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. Clin. Epigenetics 2017, 9, 22. [Google Scholar] [CrossRef] [Green Version]
Number of Cases (%) | |
---|---|
Dukes’ stages | |
Stage A | 51 (34) |
Stage B | 69 (46) |
Stage C | 18 (12) |
Stage D | 12 (8) |
Tumor size | |
T1 | 78 (52) |
T2 | 60 (40) |
T3 | 12 (8) |
Lymph node status | |
N0 | 78 (52) |
N1 | 50 (33) |
N2 | 12 (24) |
N3 | 10 (7) |
Grading | |
G1 | 68 (45) |
G2 | 43 (29) |
G3 | 39 (26) |
Patients (n = 150) | Controls (n = 150) | ||
---|---|---|---|
Women (n = 65) | Men (n = 85) | Women (n = 68) | Men (n = 82) |
Age (range) | Age (range) | Age (range) | Age (range) |
56–68 years | 53–70 years | 54–67 years | 54–67 years |
Age (average) | Age (average) | Age (average) | Age (average) |
62.1 ± 10.2 | 61.3 ± 11.2 | 60.1 ± 10.3 | 62.3 ± 10.2 |
miRNA | N | RQ Mean | RQ Min. | RQ Max. | SD |
---|---|---|---|---|---|
let-7e | 150 | 6.65 | 0.063 | 28.33 | 21.63 |
miR-1 | 150 | 2.96 | 0.002 | 92.28 | 7.40 |
miR-210 | 150 | 2.81 | 0.072 | 41.78 | 2.84 |
miR-143 | 150 | 2.35 | 0.065 | 43.53 | 4.67 |
miRNA | N | RQ Mean | RQ Min. | RQ Max. | SD |
---|---|---|---|---|---|
let-7e | 150 | 6.65 | 0.063 | 28.33 | 21.63 |
miR-1 | 150 | 2.96 | 0.002 | 92.28 | 7.40 |
miR-210 | 150 | 2.81 | 0.072 | 41.78 | 2.84 |
miR-143 | 150 | 2.35 | 0.065 | 43.53 | 4.67 |
Mann–Whitney U Test Relative to the Variable Zmn5 Bold Results Are Important p < 0.05000 | |||||||||
---|---|---|---|---|---|---|---|---|---|
miRNA | Rank Sum—Cases | Rank Sum—Controls | U | Z | p | Z | p | N—Cases | N—Controls |
let-7e | 12350.00 | 7540.000 | 3200.000 | −1.38 | 0.125 | −1.39 | 0.124 | 150 | 150 |
miR-1 | 11232.40 | 7865.500 | 4282.500 | −1.67 | 0.064 | −1.87 | 0.063 | 150 | 150 |
miR-210 | 11652.00 | 6328.000 | 3078.000 | 1.65 | 0.070 | 1.72 | 0.082 | 150 | 150 |
miR-143 | 11284.00 | 9806.00 | 2824.000 | −2.14 | 0.030 | −2.14 | 0.030 | 150 | 150 |
Variables | Spearman’s Correlation p < 0.05000 | |||
---|---|---|---|---|
N—Patients | R—Spearman | The Two-Sample t-Test T (N − 2) | p | |
let-7e and grading | 150 | 0.141 | 1.20 | 0.063 |
miR-1 and grading | 150 | 0.102 | 1.71 | 0.078 |
miR-210 and grading | 150 | 0.110 | 0.86 | 0.224 |
miR-143 and grading | 150 | 0.250 | 2.265 | 0.023 |
Variables | Spearman’s Correlation p < 0.05000 | |||
---|---|---|---|---|
N Patients | R—Spearman | The Two-Sample t-Test T (N − 2) | p | |
let-7e and Dukes’ stages | 150 | −0.074701 | −0.074 | 0.356 |
miR-1 and Dukes’ stages | 150 | −0.108 | −0.110 | 0.220 |
miR-210 and Dukes’ stages | 150 | −0.011 | −0.011 | 0.788 |
miR-143 and Dukes’ stages | 150 | −0.011 | −0.012 | 0.705 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Romanowicz, H.; Hogendorf, P.; Majos, A.; Durczyński, A.; Wojtasik, D.; Smolarz, B. Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features. Genes 2022, 13, 875. https://doi.org/10.3390/genes13050875
Romanowicz H, Hogendorf P, Majos A, Durczyński A, Wojtasik D, Smolarz B. Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features. Genes. 2022; 13(5):875. https://doi.org/10.3390/genes13050875
Chicago/Turabian StyleRomanowicz, Hanna, Piotr Hogendorf, Alicja Majos, Adam Durczyński, Dariusz Wojtasik, and Beata Smolarz. 2022. "Analysis of miR-143, miR-1, miR-210 and let-7e Expression in Colorectal Cancer in Relation to Histopathological Features" Genes 13, no. 5: 875. https://doi.org/10.3390/genes13050875